{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/prostatitis-acute/prescribing-information/co-trimoxazole/","result":{"pageContext":{"chapter":{"id":"fc84b330-890f-5ebf-b2cd-5724765b85a8","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole","depth":2,"htmlHeader":"<!-- begin field e8401c6e-57af-4bb1-86ee-aa1700abeec8 --><h2>Co-trimoxazole</h2><!-- end field e8401c6e-57af-4bb1-86ee-aa1700abeec8 -->","summary":"","htmlStringContent":"<!-- begin item 111a294e-a510-40aa-8696-aa1700abeea9 --><!-- end item 111a294e-a510-40aa-8696-aa1700abeea9 -->","topic":{"id":"73f0b35c-c49b-5f10-bb40-54ecdda0c994","topicId":"e7655eee-79f9-435e-b34e-7e3dc9576eb5","topicName":"Prostatitis - acute","slug":"prostatitis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"8803a04f-6c62-5033-ac75-2e0987df1dd9","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"23265380-0c8c-51f6-984e-87cbf6e27684","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7f11e55f-ca93-5c30-86f8-fa21b370c650","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"aa21e1cb-1af6-5deb-b54b-9cb7a12a8a11","slug":"changes","fullItemName":"Changes"},{"id":"bc4d0c33-79f0-5fe0-8655-d9dbf99bbcf5","slug":"update","fullItemName":"Update"}]},{"id":"e29f027b-46a8-5ac6-b1b7-d063f673588e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e0a59bba-34f6-512a-b3f6-19ba509165b0","slug":"goals","fullItemName":"Goals"},{"id":"b99f36b6-4383-55b0-8d6f-72dfeed4d249","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0629bcf7-67ce-5175-893c-bb0e770c16c1","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6da14859-d882-5bd2-b686-021dc2ab43ca","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90fb5a5f-3ae5-53d9-b871-bf93c899f97c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a78a1b88-9559-551a-880f-736efedb2497","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c8ae728c-472f-509a-add8-39034e05aff0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"816a1fba-211e-520e-87c1-c47a23e06dd3","slug":"definition","fullItemName":"Definition"},{"id":"42efdea9-f709-5243-8b5c-a2b75dbbba5f","slug":"causes","fullItemName":"Causes"},{"id":"9713a2ac-cc24-5443-9756-3e59fbcf65b8","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d981ad36-33da-56db-bb45-f12d69fe5543","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5b0439a7-9599-542f-b2b2-51d20cc566f2","slug":"complications","fullItemName":"Complications"}]},{"id":"6553966d-798f-5d17-bcd0-6f62f2f8b5bd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d539bec4-2427-585f-a83c-db984fc0d801","slug":"suspecting-acute-prostatitis","fullItemName":"Suspecting acute prostatitis"},{"id":"d1e691e6-d634-508e-a5c1-62018b5b24be","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"2e7dc7c5-dc32-59bf-9021-54b838ce5a9b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"398acafd-0ba3-5cf1-8c9c-8d2ccca863ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"8c56415b-f5bc-5fc1-b859-13b369ee963d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6f0cb41-8824-5f6b-9b63-19a56232237a","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"161382aa-bad2-5c17-9d1c-59f978dd6a83","slug":"ofloxacin","fullItemName":"Ofloxacin"},{"id":"6aee14ab-550d-5bdd-b0e4-d2febce26f7a","slug":"trimethoprim","fullItemName":"Trimethoprim"},{"id":"7fc380fc-24a6-5224-9d35-019f77e2d24e","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"fc84b330-890f-5ebf-b2cd-5724765b85a8","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"}]},{"id":"c4981733-d5d6-5190-b43d-7cdee7ac825c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"137ffbc9-e5c4-5f58-bfc1-4d3afb883356","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f07d427-7c9b-521d-ba7a-1a7bc564f48d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"05f5c8e4-6073-506c-909a-cef5c3cf622c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"63ca9076-27d4-5254-9eda-bcbb43177d95","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ff474396-1f31-58cd-b153-976c3894cafd","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"be6b66c2-c9cc-5d52-99dd-044e49dadfb0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9b5aeabb-1902-5659-8e0b-625f567b86e0","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"50977f3d-5737-50f5-9c23-c4a03b4539cf","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e6a33884-3040-55a0-b06b-9fcbe681c0c1","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 186eb7d3-03b3-4044-ad0c-aa1700ac36e4 --><h3>Cautions and contraindications</h3><!-- end field 186eb7d3-03b3-4044-ad0c-aa1700ac36e4 -->","summary":"","htmlStringContent":"<!-- begin item 069fb789-c3c4-4c53-b68a-aa1700ac36c7 --><!-- begin field 762ba70d-dfdf-4969-b431-aa1700ac36e4 --><ul><li><strong>Do not prescribe co-trimoxazole to people with:</strong><ul><li>Acute porpyhrias.</li><li>A history of drug-induced immune thrombocytopenia with use of trimethoprim and/or sulphonamides.</li><li>Haematological disorders (unless under specialist supervision).</li><li>Marked liver parenchymal damage.</li><li>Severe hepatic impairment.</li><li>Severe kidney impairment.</li></ul></li><li><strong>Prescribe co-trimoxazole with caution to people with:</strong><ul><li>Asthma. </li><li>Renal impairment — use half the normal dose if estimated glomerular filtration rate (eGFR) is 15–30 mL/minute/1.73 m<sup>2</sup>.</li><li>Hyperkalaemia, or taking medication that is known to cause hyperkalaemia.</li><li>Glucose-6-phosphate dehydrogenase deficiency.</li><li>Severe allergy.</li></ul></li><li><strong>Also prescribe with caution in: </strong><ul><li>People predisposed to folate deficiency.</li><li>The elderly.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 762ba70d-dfdf-4969-b431-aa1700ac36e4 --><!-- end item 069fb789-c3c4-4c53-b68a-aa1700ac36c7 -->","subChapters":[]},{"id":"a2a3ef54-8025-5fcd-8031-a49f3fe0c08d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 35ef4893-78cb-4b7a-bfdb-aa1700ac46b3 --><h3>Adverse effects</h3><!-- end field 35ef4893-78cb-4b7a-bfdb-aa1700ac46b3 -->","summary":"","htmlStringContent":"<!-- begin item 61bf379d-cc91-4642-9482-aa1700ac4692 --><!-- begin field 92a14afa-5f70-4176-aa92-aa1700ac46b3 --><ul><li><strong>Gastrointestinal </strong>— nausea, diarrhoea, (common), vomiting (uncommon).<ul><li><strong>Very rarely:</strong> glossitis, stomatitis, pseudomembranous colitis, pancreatitis.</li></ul></li><li><strong>Metabolism and nutrition </strong>— hyperkalaemia (very common).<ul><li><strong>Very rarely: </strong>hypoglycaemia, hyponatraemia, anorexia.</li></ul></li><li><strong>Nervous system</strong> — headache (common),<ul><li><strong>Very rarely:</strong> aseptic meningitis, convulsions, ataxia, vertigo, tinnitus, dizziness.</li></ul></li><li><strong>Skin and subcutaneous tissue </strong>— rash (common); drug reaction with eosinophilia and systemic symptoms (DRESS) (frequency unknown).<ul><li><strong>Very rarely:</strong> Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, exfoliative dermatitis.</li></ul></li><li><strong>Other adverse effects include: </strong><ul><li>Anaphylaxis.</li><li>Aplastic anaemia and haemolytic anaemia (older people, people with hepatic or renal failure, and people with poor folate status are more susceptible).</li><li>Arthralgia, and myalgia.</li><li>Fungal overgrowth.</li><li>Renal impairment.</li><li>Liver enzyme disturbances, cholestatic jaundice.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 92a14afa-5f70-4176-aa92-aa1700ac46b3 --><!-- end item 61bf379d-cc91-4642-9482-aa1700ac4692 -->","subChapters":[]},{"id":"d32737f1-bb84-5f8c-9798-7c93fbfa64fd","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 99b7647c-6e6a-46d7-ba03-aa1700ac5571 --><h3>Drug interactions</h3><!-- end field 99b7647c-6e6a-46d7-ba03-aa1700ac5571 -->","summary":"","htmlStringContent":"<!-- begin item 62df5fb1-7a37-4111-bf2a-aa1700ac5553 --><!-- begin field f1ad5f5a-1fa8-46bc-82f8-aa1700ac5571 --><ul><li><strong>Angiotensin-converting enzyme (ACE) inhibitors </strong>— risk of severe hyperkalaemia.</li><li><strong>Antiarrhythmics </strong>— increased risk of ventricular arrhythmias with amiodarone.</li><li><strong>Coumarins (warfarin) </strong>— effect of warfarin enhanced.<ul><li>Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul></li><li><strong>Antidiabetics </strong>— effect of sulphonylureas enhanced.</li><li><strong>Antifolates </strong>— if considered appropriate, a folate supplement should be considered for people taking antifolate drugs such as methotrexate or proguanil.</li><li><strong>Antivirals </strong>— plasma concentrations of lamivudine increased, avoid concurrent high-dose co-trimoxazole. Concurrent treatment with zidovudine may increase the risk of haematological adverse effects. Zalcitabine plasma concentrations possibly increased by co-trimoxazole.</li><li><strong>Azathioprine and mercaptopurine </strong>—<strong> </strong>increased risk of haematological toxicity in people who have had a renal transplant. However, the combination is commonly used in practice. Monitor the full blood count routinely.</li><li><strong>Clozapine </strong>— increased risk of fatal agranulocytosis. Concurrent use is contraindicated.</li><li><strong>Ciclosporin </strong>— serum creatinine levels may be increased. Possible increased risk of nephrotoxicity, monitor renal function closely. Reversible deterioration in renal function has been reported in people following renal transplantation.</li><li><strong>Digoxin </strong>—digoxin levels may be increased in the elderly if taken with trimethoprim. Monitor for digoxin adverse effects, and adjust dose accordingly.</li><li><strong>Diuretics </strong>— for older people concurrently receiving diuretics (mainly thiazides) there is an increased risk of thrombocytopenia. Hyperkalaemia may be exacerbated by conccurrent administration of diuretics, particularly potassium sparing diuretics and/or thiazide diuretics and eplerenone.</li><li><strong>Methotrexate </strong>— plasma levels may be increased.</li><li><strong>Phenytoin </strong>— phenytoin levels may be increased if taken with trimethoprim. Monitor phenytoin levels and adjust dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/prostatitis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field f1ad5f5a-1fa8-46bc-82f8-aa1700ac5571 --><!-- end item 62df5fb1-7a37-4111-bf2a-aa1700ac5553 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}